Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309428 | 0.90 | NR4A2 (0.81) | NR4A2KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL28345593 | 0.90 | NR4A2 (0.81) | NR4A2KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL19407224 | 0.88 | NR4A2 (0.79) | NR4A2KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL15420904 | 0.88 | NR4A2 (0.79) | NR4A2KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL25307454 | 0.88 | NR4A2 (0.79) | NR4A2KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL25238096 | 0.86 | NR4A2 (0.75) | NR4A2KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL31083779 | 0.86 | NR4A2 (0.74) | NR4A2KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL28791276 | 0.85 | NR4A2 (0.74) | NR4A2KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL15557161 | 0.84 | NR4A2 (0.72) | NR4A2KDM4EALDH1A1LMNAKMT2A | |
| SCHEMBL28806864 | 0.84 | NR4A2 (0.72) | NR4A2KDM4EALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9695195-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2016-06-30 | — | — | US | disclosed |
| US-9303045-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-2875012-A1 | 5HT3 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014014962-A1 | 5HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2009071577-A1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | NR4A2 1291/4885KDM4E 3782/4885ALDH1A1 1649/4885 |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | NR4A2 1291/4885KDM4E 3782/4885ALDH1A1 1649/4885 |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | NR4A2 1103/4885KDM4E 3871/4885ALDH1A1 1516/4885 |
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | NR4A2 1041/4885KDM4E 2452/4885ALDH1A1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.